PharmaKure Submits MHRA CTA for Phase 2a Clinical Trial of PK051 in Patients with Mild Cognitive Impairment

PK051 is a combined drug that targets disaggregates of amyloid-β proteins. There is increasing scientific acceptance that overproduction and/or deposition of amyloid-β is the initial event in Alzheimer’s Disease pathology.